{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:45:57Z","timestamp":1787244357562,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020963","name":"Moonshot Research and Development Program","doi-asserted-by":"publisher","award":["JPMJMS2025"],"award-info":[{"award-number":["JPMJMS2025"]}],"id":[{"id":"10.13039\/501100020963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JPJSCCA20200006"],"award-info":[{"award-number":["JPJSCCA20200006"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Neutropenia can easily progress to febrile neutropenia and is a risk factor for life-threatening infections. Predicting and preventing severe neutropenia can help avoid such infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>This study aimed to develop an optimal model using advanced statistical methods to predict neutropenia after 5-fluorouracil\/cisplatin chemotherapy for esophageal cancer and to create a nomogram for clinical application.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>Patients who received 5-fluorouracil\/cisplatin chemotherapy at Chiba University Hospital, Japan, between January 2011 and March 2021 were included. Clinical parameters were measured before the first, second, and third chemotherapy cycles and were randomly divided by patient into a training cohort (60%) and test cohort (40%). The predictive performance of Logistic, Stepwise, Lasso, and GLMMLasso models was evaluated by the area under the receiver-operating characteristic curve (AUC). A nomogram based on GLMMLasso was developed, and the accuracy of probabilistic predictions was evaluated by the Brier score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The AUC for the first cycle of chemotherapy was 0.781 for GLMMLasso, 0.751 for Lasso, 0.697 for Stepwise, and 0.669 for Logistic. The respective AUCs for GLMMLasso in the second and third cycles were 0.704 and 0.900. The variables selected by GLMMLasso were cisplatin dose, 5-fluorouracil dose, use of leucovorin, sex, cholinesterase, and platelets. A nomogram predicting neutropenia was created based on each regression coefficient. The Brier score for the nomogram was 0.139.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We have developed a predictive model with high performance using GLMMLasso. Our nomogram can represent risk visually and may facilitate the assessment of the probability of chemotherapy-induced severe neutropenia in clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11096-024-01836-5","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T07:43:37Z","timestamp":1732175017000},"page":"990-1000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a robust predictive model for neutropenia after esophageal cancer chemotherapy using GLMMLasso"],"prefix":"10.1007","volume":"47","author":[{"given":"Shuhei","family":"Sugaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-9208","authenticated-orcid":false,"given":"Masashi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiryo","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"6","key":"1836_CR1","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","volume":"13","author":"DJ Uhlenhopp","year":"2020","unstructured":"Uhlenhopp DJ, Then EO, Sunkara T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010\u201321. https:\/\/doi.org\/10.1007\/s12328-020-01237-x.","journal-title":"Clin J Gastroenterol"},{"issue":"6","key":"1836_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00000421-199612000-00009","volume":"19","author":"J Feliu","year":"1996","unstructured":"Feliu J, Gonz\u00e1lez Bar\u00f3n M, Garc\u00eda Gir\u00f3n C, et al. Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ cooperative group, Spain. Am J Clin Oncol. 1996;19(6):577\u201380. https:\/\/doi.org\/10.1097\/00000421-199612000-00009.","journal-title":"Am J Clin Oncol"},{"issue":"107\u2013108","key":"1836_CR3","first-page":"802","volume":"58","author":"M Kogo","year":"2011","unstructured":"Kogo M, Watahiki M, Sunaga T, et al. Analysis of the risk factors for myelosuppression after chemoradiotherapy involving 5-fluorouracil and platinum for patients with esophageal cancer. Hepatogastroenterology. 2011;58(107\u2013108):802\u20138.","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"1836_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12957-019-1665-x","volume":"17","author":"Y Ohkura","year":"2019","unstructured":"Ohkura Y, Ueno M, Udagawa H. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World J Surg Oncol. 2019;17(1):125. https:\/\/doi.org\/10.1186\/s12957-019-1665-x.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"1836_CR5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00520-019-05001-x","volume":"28","author":"H Nomura","year":"2020","unstructured":"Nomura H, Hatogai K, Maki Y, et al. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer. 2020;28(4):1849\u201354. https:\/\/doi.org\/10.1007\/s00520-019-05001-x.","journal-title":"Support Care Cancer"},{"issue":"5","key":"1836_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/00273171.2015.1036965","volume":"50","author":"DM McNeish","year":"2015","unstructured":"McNeish DM. Using lasso for predictor selection and to assuage overfitting: a method long overlooked in behavioral sciences. Multivariate Behav Res. 2015;50(5):471\u201384. https:\/\/doi.org\/10.1080\/00273171.2015.1036965.","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"1836_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1214\/aos\/1176345513","volume":"9","author":"D Pregibon","year":"1981","unstructured":"Pregibon D. Logistic regression diagnostics. Ann Stat. 1981;9(4):705\u201324. https:\/\/doi.org\/10.1214\/aos\/1176345513.","journal-title":"Ann Stat"},{"issue":"1","key":"1836_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1.","journal-title":"J Stat Softw"},{"issue":"10","key":"1836_CR9","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/bjc.2015.122","volume":"112","author":"W Ichikawa","year":"2015","unstructured":"Ichikawa W, Uehara K, Minamimura K, et al. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Br J Cancer. 2015;112(10):1709\u201316. https:\/\/doi.org\/10.1038\/bjc.2015.122.","journal-title":"Br J Cancer"},{"issue":"1","key":"1836_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clgc.2016.05.012","volume":"15","author":"Y Hirasawa","year":"2017","unstructured":"Hirasawa Y, Nakashima J, Sugihara T, et al. Development of a nomogram for predicting severe neutropenia associated with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15(1):176\u201381. https:\/\/doi.org\/10.1016\/j.clgc.2016.05.012.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"1836_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/jjco\/hyv203","volume":"46","author":"E Sakaida","year":"2016","unstructured":"Sakaida E, Iwasawa S, Kurimoto R, et al. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study. Jpn J Clin Oncol. 2016;46(4):370\u20137. https:\/\/doi.org\/10.1093\/jjco\/hyv203.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1836_CR12","first-page":"25","volume":"1","author":"A Groll","year":"2017","unstructured":"Groll A. glmmLasso: variable selection for generalized linear mixed models by L1-penalized estimation. R Package Version. 2017;1(1):25.","journal-title":"R Package Version"},{"issue":"2","key":"1836_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11222-012-9359-z","volume":"24","author":"A Groll","year":"2014","unstructured":"Groll A, Tutz G. Variable selection for generalized linear mixed models by L 1-penalized estimation. Stat Comput. 2014;24(2):137\u201354.","journal-title":"Stat Comput"},{"issue":"3\u20134","key":"1836_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/10428190009089435","volume":"37","author":"T Intragumtornchai","year":"2000","unstructured":"Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 2000;37(3\u20134):351\u201360. https:\/\/doi.org\/10.3109\/10428190009089435.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1836_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/annonc\/mdn655","volume":"20","author":"M Moreau","year":"2009","unstructured":"Moreau M, Klastersky J, Schwarzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol. 2009;20(3):513\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn655.","journal-title":"Ann Oncol"},{"issue":"12","key":"1836_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/jjco\/hys170","volume":"42","author":"RA Makihara","year":"2012","unstructured":"Makihara RA, Makino Y, Yamamoto N, et al. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy. Jpn J Clin Oncol. 2012;42(12):1187\u201391. https:\/\/doi.org\/10.1093\/jjco\/hys170.","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"1836_CR17","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/jco.2006.10.4182","volume":"26","author":"M Schwab","year":"2008","unstructured":"Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131\u20138. https:\/\/doi.org\/10.1200\/jco.2006.10.4182.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1836_CR18","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.ccr-18-3378","volume":"25","author":"E Kawakami","year":"2019","unstructured":"Kawakami E, Tabata J, Yanaihara N, et al. Application of artificial intelligence for preoperative diagnostic and prognostic prediction in epithelial ovarian cancer based on blood biomarkers. Clin Cancer Res. 2019;25(10):3006\u201315. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-3378.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1836_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/s0006-2952(99)00157-4","volume":"58","author":"K Raghunathan","year":"1999","unstructured":"Raghunathan K, Priest DG. Modulation of fluorouracil antitumor activity by folic acid in a murine model system. Biochem Pharmacol. 1999;58(5):835\u20139. https:\/\/doi.org\/10.1016\/s0006-2952(99)00157-4.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"1836_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1200\/jco.1992.10.7.1171","volume":"10","author":"G Milano","year":"1992","unstructured":"Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10(7):1171\u20135. https:\/\/doi.org\/10.1200\/jco.1992.10.7.1171.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1836_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1215\/15228517-2008-120","volume":"11","author":"TS Armstrong","year":"2009","unstructured":"Armstrong TS, Cao Y, Scheurer ME, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 2009;11(6):825\u201332. https:\/\/doi.org\/10.1215\/15228517-2008-120.","journal-title":"Neuro Oncol"},{"issue":"8","key":"1836_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1248\/bpb.b20-00266","volume":"43","author":"M Uchida","year":"2020","unstructured":"Uchida M, Yamaguchi Y, Hosomi S, et al. Risk factors for febrile neutropenia induced by docetaxel chemotherapy in patients with non-small cell lung cancer. Biol Pharm Bull. 2020;43(8):1235\u201340. https:\/\/doi.org\/10.1248\/bpb.b20-00266.","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"1836_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jca.20246","volume":"25","author":"ZN Ozkurt","year":"2010","unstructured":"Ozkurt ZN, Yegin ZA, Suyani E, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher. 2010;25(5):280\u20136. https:\/\/doi.org\/10.1002\/jca.20246.","journal-title":"J Clin Apher"},{"issue":"8","key":"1836_CR24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.ejca.2004.01.029","volume":"40","author":"P Nieboer","year":"2004","unstructured":"Nieboer P, de Vries EG, Vellenga E, et al. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Eur J Cancer. 2004;40(8):1199\u2013207. https:\/\/doi.org\/10.1016\/j.ejca.2004.01.029.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1836_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13539-012-0083-5","volume":"4","author":"L Santarpia","year":"2013","unstructured":"Santarpia L, Grandone I, Contaldo F, et al. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2013;4(1):31\u20139. https:\/\/doi.org\/10.1007\/s13539-012-0083-5.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"12","key":"1836_CR26","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1002\/1097-0142(19931215)72:12<3715::aid-cncr2820721225>3.0.co;2-w","volume":"72","author":"LE Davis","year":"1993","unstructured":"Davis LE, Lenkinski RE, Shinkwin MA, et al. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Cancer. 1993;72(12):3715\u201322. https:\/\/doi.org\/10.1002\/1097-0142(19931215)72:12%3c3715::aid-cncr2820721225%3e3.0.co;2-w.","journal-title":"Cancer"},{"issue":"1","key":"1836_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ncp.10588","volume":"36","author":"DC Evans","year":"2021","unstructured":"Evans DC, Corkins MR, Malone A, et al. The use of visceral proteins as nutrition markers: an ASPEN position paper. Nutr Clin Pract. 2021;36(1):22\u20138. https:\/\/doi.org\/10.1002\/ncp.10588.","journal-title":"Nutr Clin Pract"},{"issue":"4","key":"1836_CR28","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s10388-019-00681-0","volume":"16","author":"K Ishii","year":"2019","unstructured":"Ishii K, Tsubosa Y, Niihara M, et al. Changes in the nutritional status of elderly patients after esophagectomy. Esophagus. 2019;16(4):408\u201312. https:\/\/doi.org\/10.1007\/s10388-019-00681-0.","journal-title":"Esophagus"},{"issue":"6","key":"1836_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bjorl.2019.04.008","volume":"86","author":"M Gundog","year":"2020","unstructured":"Gundog M, Basaran H, Bozkurt O, et al. A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. Braz J Otorhinolaryngol. 2020;86(6):676\u201386. https:\/\/doi.org\/10.1016\/j.bjorl.2019.04.008.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"3","key":"1836_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/cam4.4477","volume":"11","author":"YT Jiang","year":"2022","unstructured":"Jiang YT, Chen KH, Yang J, et al. Efficiency of high cumulative cisplatin dose in high- and low-risk patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Med. 2022;11(3):715\u201327. https:\/\/doi.org\/10.1002\/cam4.4477.","journal-title":"Cancer Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01836-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T01:11:19Z","timestamp":1757121079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01836-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1836"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01836-5","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}